Discontinued — last reported Q4 '25
TE Connectivity Acquisitions decreased by 100.0% to $0.00 in Q3 2025 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 57.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.00M | $297.00M | $100.00M | $2.00M | $14.00M | $104.00M | $109.00M | -$1.00M | $0.00 | $2.00M | $349.00M | -$10.00M | $0.00 | $0.00 | $325.00M | -$4.00M | $2.31B | $0.00 |
| QoQ Change | — | >999% | -66.3% | -98.0% | +600.0% | +642.9% | +4.8% | -100.9% | +100.0% | — | >999% | -102.9% | +100.0% | — | — | -101.2% | >999% | -100.0% |
| YoY Change | — | — | — | — | -26.3% | -65.0% | +9.0% | -150.0% | -100.0% | -98.1% | +220.2% | -900.0% | — | -100.0% | -6.9% | +60.0% | — | — |